Compare FTAI Aviation Ltd (FTAI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Spyre Therapeutics Inc. Common Stock — how do they compare? FTAI Aviation Ltd trades at $159.09 (market cap $17.14B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: FTAI Aviation Ltd is far larger — about 2.3× Spyre Therapeutics Inc. Common Stock's market cap, and FTAI Aviation Ltd pays a 1.2% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 24 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FTAI | SYRE | |
|---|---|---|
Market Cap | $17.14B | $7.52B |
Volume | 3,282,791 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $310.04 | $108.92 |
52-Week Low | $152.80 | $22.18 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $20.25B | $6.52B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $166.87, up 0.81% today, but technical indicators signal a bearish trend with key support at $163 and resistance at $169. The company reported strong 2025 revenue of $2.51 billion and net income of $501 million, though recent quarters have missed EPS expectations. Recent developments include a $500 million share buyback program and a strategic acquisition of 27 Boeing 737-700 aircraft, highlighting growth initiatives in aerospace services.
The outlook is mixed: analyst consensus is unanimously bullish with a $321.25 price target, but risks include volatile cash flows and competitive pressures. Upside potential hinges on execution of the buyback and aerospace segment growth, while earnings misses and negative operating cash flow pose near-term challenges for investors.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
